邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

急性缺血性卒中血管再通治疗研究历程

热孜亚·阿布都许库尔,  吕珊,  贺耀德,  靳航,  郭珍妮,  杨弋

downloadPDF
文章导航 > 协和医学杂志  > 2020 >  11(2): 162-169
热孜亚·阿布都许库尔, 吕珊, 贺耀德, 靳航, 郭珍妮, 杨弋. 急性缺血性卒中血管再通治疗研究历程[J]. 协和医学杂志, 2020, 11(2): 162-169. doi: 10.3969/j.issn.1674-9081.20190273
引用本文: 热孜亚·阿布都许库尔, 吕珊, 贺耀德, 靳航, 郭珍妮, 杨弋. 急性缺血性卒中血管再通治疗研究历程[J]. 协和医学杂志, 2020, 11(2): 162-169. doi: 10.3969/j.issn.1674-9081.20190273
shu
Reziya ABUDUXUKUER, Shan LYU, Yao-de HE, Hang JIN, Zhen-ni GUO, Yi YANG. Rearch Course of Reperfusion Therapy for Acute Ischemic Stroke[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(2): 162-169. doi: 10.3969/j.issn.1674-9081.20190273
Citation: Reziya ABUDUXUKUER, Shan LYU, Yao-de HE, Hang JIN, Zhen-ni GUO, Yi YANG. Rearch Course of Reperfusion Therapy for Acute Ischemic Stroke[J]. Medical Journal of Peking Union Medical College Hospital, 2020, 11(2): 162-169. doi: 10.3969/j.issn.1674-9081.20190273
shu

急性缺血性卒中血管再通治疗研究历程

doi: 10.3969/j.issn.1674-9081.20190273

  • 吉林大学第一医院神经内科, 长春 130021

基金项目: 

吉林省脑血管病防治体系及急性期救治网络建设项目 2017F003

详细信息
    通讯作者:

    杨弋 电话:0431-88782378, E-mail:doctoryangyi@163.com

  • 中图分类号: R45;R743.3;R-1

Rearch Course of Reperfusion Therapy for Acute Ischemic Stroke

  • Department of Neurology, The First Hospital of Jilin University, Changchun 130021, China

More Information

    摘要
  • 摘要: 急性缺血性卒中(acute ischemic stroke, AIS)是最常见的卒中类型, 具有高发病率、高死亡率、高致残率的特点。在时间窗内快速进行血管再通、实现血运重建、挽救缺血半暗带是治疗AIS的关键, 主要包括静脉溶栓治疗和血管内治疗。AIS血管再通治疗从静脉溶栓发展到血管内治疗, 经历了30多年的研究历程, 大致可分为3个阶段:第一阶段, 探索静脉溶栓药物, 开创卒中的静脉溶栓时代; 第二阶段, 探索溶栓药物更安全、有效的剂量和更合理的时间窗; 第三阶段, 取栓治疗兴起并飞速发展, 使AIS患者的治疗方法选择多样化、个体化, 根据患者的发病时间、严重程度及影像学改变等, 选择静脉溶栓治疗、桥接治疗(静脉溶栓联合血管内治疗)或单纯血管内治疗。
    Abstract: Acute ischemic stroke(AIS), characterized by its high morbidity, high mortality, and high disability, is the most common subtype of stroke. Rapidly recanalizing the occluded arteries to salvage ischemic parenchyma in the early stage is essential to treat AIS, which mainly includes intravenous thrombolysis and endovascular treatment. The reperfusion therapy of AIS has been studied for over thirty years developing from intravenous thrombolysis(IVT) to endovascular treatment. There are three main stages in the evolution of reperfusion therapy:(1)investigating thrombolytic agents, which commenced the era of IVT in treating AIS; (2)investigating the dose and time window of thrombolytic agents to maximize the benefit and minimize the risk of IVT; (3)investigating mechanical thrombectomy for AIS, which contributes to the diversification and individualization of reperfusion therapy. Currently, IVT, bridging therapy, and direct mechanical thrombectomy can be applied to treating AIS according to the duration from the onset, the severity of clinical manifestation, and findings in the imaging examination.
    利益冲突  无
    • HTML全文
    • 参考文献(74)
  • [1] Wang W, Jiang B, Sun H, et al. Prevalence, Incidence, and Mortality of Stroke in China:Results from a Nationwide Population-Based Survey of 480687 Adults[J]. Circulation, 2017, 135:759-771. http://svn.bmj.com/lookup/ijlink?linkType=ABST&journalCode=circulationaha&resid=135/8/759&atom=%2Fsvnbmj%2F2%2F3%2F132.atom
    [2] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组.中国急性缺血性脑卒中诊治指南2018[J].中华神经科杂志, 2018, 51:666-682. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhsjk201809005
    [3] Sussman BJ, Fitch TS. Thrombolysis with fibrinolysin in cerebral arterial occlusion[J]. J Am Med Assoc, 1958, 167:1705-1709. http://onlinelibrary.wiley.com/resolve/reference/PMED?id=13563167
    [4] 张和.卒中治疗——Zivin与阿替普酶[J].中国卒中杂志, 2017, 12:727-728. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgzzzz201708015
    [5] Zivin JA, Fisher M, Degirolami U, et al. Tissue plasm-inogen activator reduces neurological damage after cerebral embolism[J]. Science, 1985, 230:1289-1292. http://www.ncbi.nlm.nih.gov/pubmed/3934754
    [6] National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke[J]. N Engl J Med, 1995, 333:1581-1587.
    [7] Adams HP Jr, Brott TG, Furlan AJ, et al. Guidelines for Thrombolytic Therapy for Acute Stroke:a Supplement to the Guidelines for the Management of Patients with Acute Ischemic Stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association[J]. Circulation, 1996, 94:1167-1174. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=10.1177/0148607102026001011
    [8] Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study(ECASS)[J]. JAMA, 1995, 274:1017-1025. http://pmj.bmj.com/external-ref?access_num=10.1001/jama.1995.03530130023023&link_type=DOI
    [9] Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke(ECASS Ⅱ). Second European-Australasian Acute Stroke Study Investigators[J]. Lancet, 1998, 352:1245-1251. http://www.europepmc.org/abstract/MED/9788453
    [10] Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator(Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study:a randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke[J]. JAMA, 1999, 282:2019-2026. http://www.tandfonline.com/servlet/linkout?suffix=CIT0028&dbid=16&doi=10.1517%2F14656560802521650&key=10.1001%2Fjama.282.21.2019
    [11] Clark WM, Albers GW, Madden KP, Hamilton S. The rtPA(alteplase) 0- to 6-hour acute stroke trial, part A(A0276g):results of a double-blind, placebo-controlled, multicenter study. Thromblytic therapy in acute ischemic stroke study investigators[J]. Stroke, 2000, 31:811-816. http://bja.oxfordjournals.org/cgi/ijlink?linkType=ABST&journalCode=strokeaha&resid=31/4/811
    [12] Hacke W, Donnan G, Fieschi C, et al. Association of outcome with early stroke treatment:pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials[J]. Lancet, 2004, 363:768-774. http://www.ncbi.nlm.nih.gov/pubmed/15016487
    [13] 卢海涛, 张小年, 周维金.缺血性脑卒中患者的早期处理指南(四)[J].中国康复理论与实践, 2004, 10:121-125. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgkfllysj200402029
    [14] Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke[J]. N Engl J Med, 2008, 359:1317-1329. doi:  10.1007/s00390-008-0018-8
    [15] Davis SM, Donnan GA, Parsons MW, et al. Effects of alteplase beyond 3 h after stroke in the Echoplanar Imaging Thrombolytic Evaluation Trial(EPITHET):a placebo-controlled randomised trial[J]. Lancet Neurol, 2008, 7:299-309. http://brain.oxfordjournals.org/lookup/external-ref?access_num=18296121&link_type=MED&atom=%2Fbrain%2Fearly%2F2015%2F03%2F23%2Fbrain.awv071.atom
    [16] Lees KR, Bluhmki E, von Kummer R, et al. Time to treatment with intravenous alteplase and outcome in stroke:an updated pooled analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials[J]. Lancet, 2010, 375:1695-1703.
    [17] 中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中国全科医学, 2011, 14:4013-4017. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zgqkyx201135004
    [18] 金征宇, 孙昊.新时代放射影像临床诊疗路径的思考[J].协和医学杂志, 2019, 10:2-5. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=xhyx201901002
    [19] Thomalla G, Rossbach P, Rosenkranz M, et al. Negative fluid-attenuated inversion recovery imaging identifies acute ischemic stroke at 3 hours or less[J]. Ann Neurol, 2009, 65:724-732. doi:  10.1002/ana.21651/full
    [20] Thomalla G, Fiebach JB, Østergaard L, et al. A multi-center, randomized, double-blind, placebo-controlled trial to test efficacy and safety of magnetic resonance imaging-based thrombolysis in wake-up stroke(WAKE-UP)[J]. Int J Stroke, 2014, 9:829-836. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=WK_MED201810241505
    [21] Thomalla G, Simonsen CZ, Boutitie F, et al. MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset[J].N Engl J Med, 2018, 379:611-622. http://www.ncbi.nlm.nih.gov/pubmed/29766770
    [22] Amiri H, Bluhmki E, Bendszus M, et al. European Cooperative Acute Stroke Study-4:Extending the time for thrombolysis in emergency neurological deficits ECASS-4:ExTEND[J]. Int J Stroke, 2016, 11:260-267. doi:  10.1177/1747493015620805
    [23] Ma H, Parsons MW, Christensen S, et al. A multicentre, randomized, double-blinded, placebo-controlled Phase Ⅲ study to investigate EXtending the time for Thrombolysis in Emergency Neurological Deficits(EXTEND)[J]. Int J Stroke, 2012, 7:74-80.
    [24] Campbell BCV, Ma H, Ringleb PA, et al. Extending thrombolysis to 4.5-9 h and wake-up stroke using perfusion imaging:a systematic review and meta-analysis of individual patient data[J]. Lancet, 2019, 394:139-147. http://www.sciencedirect.com/science/article/pii/S0140673619310530
    [25] Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke:2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke:A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association[J]. Stroke, 2019, 50:e344-e418.
    [26] Huang Y, Sharma VK, Robinson T, et al. Rationale, design, and progress of the ENhanced Control of Hyperten-sion ANd Thrombolysis strokE stuDy(ENCHANTED) trial:An international multicenter 2×2 quasi-factorial randomized controlled trial of low- vs. standard-dose rt-PA and early intensive vs. guideline-recommended blood pressure lowering in patients with acute ischaemic stroke eligible for thrombolysis treatment[J]. Int J Stroke, 2015, 10:778-788. doi:  10.1111/ijs.12486
    [27] Coutts SB, Berge E, Campbell BC, et al. Tenecteplase for the treatment of acute ischemic stroke:A review of completed and ongoing randomized controlled trials[J]. Int J Stroke, 2018, 13:885-892. doi:  10.1177/1747493018790024
    [28] Bivard A, Huang X, McElduff P, et al. Impact of Computed Tomography Perfusion Imaging on the Response to Tenecteplase in Ischemic Stroke:Analysis of 2 Randomized Controlled Trials[J]. Circulation, 2017, 135:440-448. doi:  10.1161/CIRCULATIONAHA.116.022582
    [29] Campbell BC, Mitchell PJ, Churilov L, et al. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke[J]. N Engl J Med, 2018, 378:1573-1582. doi:  10.1056/NEJMoa1716405
    [30] Campbell BC, Mitchell PJ, Churilov L, et al. Determining the optimal dose of tenecteplase before endovascular therapy for ischemic stroke(EXTEND-IA TNK Part 2):A multicenter, randomized, controlled study[J]. Int J Stroke, 2019. doi: 10.1177/1747493019879652.[Epub ahead of print].
    [31] Fletcher AP, Alkjaersig N, Lewis M, et al. A pilot study of urokinase therapy in cerebral infarction[J]. Stroke, 1976, 7:135-142. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=WK_LWW2017052520654873
    [32] 饶明俐, 张秉枢, 常庆有.尿激酶治疗脑血管关闭30例临床分析[J].白求恩医科大学学报, 1978, (04):48-53. http://search.cnki.net/down/default.aspx?filename=BQEB197804007&dbcode=CJFD&year=1978&dflag=pdfdown
    [33] 国家"九五"公关课题协作组.急性脑梗死(6 h以内)静脉溶栓治疗[J].中风与神经疾病杂志, 2004, 18:259-261. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zfysjjbzz200105001
    [34] 国家"九五"公关课题协作组.急性脑梗死六小时以内的静脉溶栓治疗[J].中华神经科杂志, 2002, 35:210-213. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhsjk200204007
    [35] Wang Y, Liao X, Zhao X, et al. Using recombinant tissue plasminogen activator to treat acute ischemic stroke in China:analysis of the results from the Chinese National Stroke Registry(CNSR)[J]. Stroke, 2011, 42:1658-1664. doi:  10.1161/STROKEAHA.110.604249
    [36] Wahlgren N, Ahmed N, Dávalos A, et al. Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study(SITS-MOST):an observational study[J]. Lancet, 2007, 369:275-282. doi:  10.1016/S0140-6736(07)60149-4
    [37] Leys D, Cordonnier C, Debette S, et al. Facilities available in French hospitals treating acute stroke patients:comparison with 24 other European countries[J]. J Neurol, 2009, 256:867-873. doi:  10.1007/s00415-009-5029-2
    [38] Del Zoppo GJ, Higashida RT, Furlan AJ, et al. PROACT:a phase Ⅱ randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism[J]. Stroke, 1998, 29:4-11. doi:  10.1161/01.STR.29.1.4
    [39] Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT Ⅱ study:a randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism[J]. JAMA, 1999, 282:2003-2011. doi:  10.1001/jama.282.21.2003
    [40] Lewandowski CA, Frankel M, Tomsick TA, et al. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke:Emergency Management of Stroke(EMS) Bridging Trial[J]. Stroke, 1999, 30:2598-2605. doi:  10.1161/01.STR.30.12.2598
    [41] Gobin YP, Starkman S, Duckwiler GR, et al. MERCI 1:a phase 1 study of Mechanical Embolus Removal in Cerebral Ischemia[J]. Stroke, 2004, 35:2848-2854. doi:  10.1161/01.STR.0000147718.12954.60
    [42] 中华医学会神经病学分会, 中华医学会神经病学分会神经血管介入协作组, 急性缺血性脑卒中介入诊疗指南撰写组.中国急性缺血性脑卒中早期血管内介入诊疗指南[J].中华神经科杂志, 2015, 48:356-361. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhsjk201505002
    [43] IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke:the Interventional Management of Stroke Study[J]. Stroke, 2004, 35:904-911. doi:  10.1161/01.STR.0000121641.77121.98
    [44] IMS Ⅱ Trial Investigators. The Interventional Management of Stroke(IMS) Ⅱ Study[J]. Stroke, 2007, 38:2127-2135. doi:  10.1161/STROKEAHA.107.483131
    [45] Smith WS. Safety of mechanical thrombectomy and intraven-ous tissue plasminogen activator in acute ischemic stroke. Results of the multi Mechanical Embolus Removal in Cerebral Ischemia(MERCI) trial, part I[J]. AJNR Am J Neuroradiol, 2006, 27:1177-1182.
    [46] Ogawa A, Mori E, Minematsu K, et al. Randomized trial of intraarterial infusion of urokinase within 6 hours of middle cerebral artery stroke:the middle cerebral artery embolism local fibrinolytic intervention trial(MELT) Japan[J]. Stroke, 2007, 38:2633-2639. doi:  10.1161/STROKEAHA.107.488551
    [47] Broderick JP, Palesch YY, Demchuk AM, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke[J]. N Engl J Med, 2013, 368:893-903. doi:  10.1056/NEJMoa1214300
    [48] Ciccone A, Valvassori L, Nichelatti M, et al. Endovascular treatment for acute ischemic stroke[J]. N Engl J Med, 2013, 368:904-913. doi:  10.1056/NEJMoa1213701
    [49] Kidwell CS, Jahan R, Gornbein J, et al. A trial of imaging selection and endovascular treatment for ischemic stroke[J]. N Engl J Med, 2013, 368:914-923. doi:  10.1056/NEJMoa1212793
    [50] Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the Merci Retriever in patients with acute ischaemic stroke(SWIFT):a randomised, parallel-group, non-inferiority trial[J]. Lancet, 2012, 380:1241-1249. doi:  10.1016/S0140-6736(12)61384-1
    [51] Nogueira RG, Lutsep HL, Gupta R, et al. TREVO versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke(TREVO 2):a randomised trial[J]. Lancet, 2012, 380:1231-1240. doi:  10.1016/S0140-6736(12)61299-9
    [52] Berkhemer OA, Fransen PS, Beumer D, et al. A rando-mized trial of intraarterial treatment for acute ischemic stroke[J]. N Engl J Med, 2015, 372:11-20. doi:  10.1056/NEJMoa1411587
    [53] Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular treatment of ischemic stroke[J]. N Engl J Med, 2015, 372:1019-1030. doi:  10.1056/NEJMoa1414905
    [54] Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with perfusion-imaging selection[J]. N Engl J Med, 2015, 372:1009-1018. doi:  10.1056/NEJMoa1414792
    [55] Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-PA alone in stroke[J]. N Engl J Med, 2015, 372:2285-2295. doi:  10.1056/NEJMoa1415061
    [56] Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in ischemic stroke[J]. N Engl J Med, 2015, 372:2296-2306. doi:  10.1056/NEJMoa1503780
    [57] Badhiwala JH, Nassiri F, Alhazzani Waleed, et al. Endovascular Thrombectomy for Acute Ischemic Stroke:A Meta-analysis[J]. JAMA, 2015, 314:1832-1843. doi:  10.1001/jama.2015.13767
    [58] Bracard S, Ducrocq X, Mas JL, et al. Mechanical thrombectomy after intravenous alteplase versus alteplase alone after stroke(THRACE):a randomised controlled trial[J]. Lancet Neurol, 2016, 15:1138-1147. doi:  10.1016/S1474-4422(16)30177-6
    [59] Powers WJ, Derdeyn CP, Biller J, et al. 2015 American Heart Association/American Stroke Association Focused Update of the 2013 Guidelines for the Early Management of Patients With Acute Ischemic Stroke Regarding Endovascular Treatment:A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association[J]. Stroke, 2015, 46:3020-3035. doi:  10.1161/STR.0000000000000074
    [60] Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct[J]. N Engl J Med, 2018, 378:11-21. doi:  10.1056/NEJMoa1706442
    [61] Albers GW, Marks MP, Kemp S, et al. Thrombectomy for Stroke at 6 to 16 Hours with Selection by Perfusion Imaging[J]. N Engl J Med, 2018, 378:708-718. doi:  10.1056/NEJMoa1713973
    [62] 中华医学会神经病学分会, 中华医学会神经病学分会脑血管病学组, 中华医学会神经病学分会神经血管介入协作组.中国急性缺血性脑卒中早期血管内介入诊疗指南2018[J].中华神经科杂志, 2018, 51:683-691. http://www.wanfangdata.com.cn/details/detail.do?_type=perio&id=zhsjk201809006
    [63] Liu X, Dai Q, Ye R, et al. Endovascular treatment versus standard medical treatment for vertebrobasilar artery occlusion(BEST):an open-label, randomised controlled trial[J]. Lancet Neurol, 2020, 19:115-122. doi:  10.1016/S1474-4422(19)30395-3
    [64] Toni D, Mangiafico S, Agostoni E, et al. Intravenous thrombolysis and intra-arterial interventions in acute ischemic stroke:Italian Stroke Organisation(ISO)-SPREAD guidelines[J]. Int J Stroke, 2015, 10:1119-1129. doi:  10.1111/ijs.12604
    [65] Wahlgren N, Moreira T, Michel P, et al. Mechanical thrombectomy in acute ischemic stroke:Consensus statement by ESO-Karolinska Stroke Update 2014/2015, supported by ESO, ESMINT, ESNR and EAN[J]. Int J Stroke, 2016, 11:134-147. doi:  10.1177/1747493015609778
    [66] Coutinho JM, Liebeskind DS, Slater LA, et al. Combined Intravenous Thrombolysis and Thrombectomy vs Thrombecto-my Alone for Acute Ischemic Stroke:A Pooled Analysis of the SWIFT and STAR Studies[J]. JAMA Neurol, 2017, 74:268-274. doi:  10.1001/jamaneurol.2016.5374
    [67] Saqqur M, Uchino K, Demchuk AM, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke[J]. Stroke, 2007, 38:948-954. doi:  10.1161/01.STR.0000257304.21967.ba
    [68] Guedin P, Larcher A, Decroix JP, et al. Prior IV Thrombolysis Facilitates Mechanical Thrombectomy in Acute Ischemic Stroke[J]. J Stroke Cerebrovasc Dis, 2015, 24:952-957. doi:  10.1016/j.jstrokecerebrovasdis.2014.12.015
    [69] Behme D, Kabbasch C, Kowoll A, et al. Intravenous Thrombolysis Facilitates Successful Recanalization with Stent-Retriever Mechanical Thrombectomy in Middle Cerebral Artery Occlusions[J]. J Stroke Cerebrovasc Dis, 2016, 25:954-959. doi:  10.1016/j.jstrokecerebrovasdis.2016.01.007
    [70] Kaesmacher J, Kleine JF. Bridging Therapy with i.v. rtPA in MCA Occlusion Prior to Endovascular Thrombectomy:a Double-Edged Sword?[J]. Clin Neuroradiol, 2018, 28:81-89. doi:  10.1007/s00062-016-0533-0
    [71] Almekhlafi MA, Hill MD, Roos YM, et al. Stroke Laterality Did Not Modify Outcomes in the HERMES Meta-Analysis of Individual Patient Data of 7 Trials[J]. Stroke, 2019, 50:2118-2124. doi:  10.1161/STROKEAHA.118.023102
    [72] Saver JL, Goyal M, van der Lugt A, et al. Time to Treatment With Endovascular Thrombectomy and Outcomes From Ischemic Stroke:A Meta-analysis[J]. JAMA, 2016, 316:1279-1288. doi:  10.1001/jama.2016.13647
    [73] Wang H, Zi W, Hao Y, et al. Direct endovascular treatment:an alternative for bridging therapy in anterior circulation large-vessel occlusion stroke[J]. Eur J Neurol, 2017, 24:935-943. doi:  10.1111/ene.13311
    [74] Liu M, Li G. Is Direct Endovascular Treatment as an Alternative of Bridging Therapy in Acute Stroke Patients with Large Vessel Occlusion?[J]. J Stroke Cerebrovasc Dis, 2019, 28:531-541. doi:  10.1016/j.jstrokecerebrovasdis.2018.10.007
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  523
  • HTML全文浏览量:  36
  • PDF下载量:  152
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-12-09
  • 刊出日期:  2020-03-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！